ELITE PHARMACEUTICALS, INC. (OTCMKTS:ELTP) Files An 8-K Results of Operations and Financial Condition
Item 2.02.Results of Operations and Financial Condition.
On June 14, 2017, Elite Pharmaceuticals, Inc. (Elite or the
Company) filed its annual report on Form 10-K for the year ended
March 31, 2017 and, thereafter, issued a press release announcing
its financial results for the fourth quarter and the fiscal year
2017 then ended. A copy of the press release is furnished as
Exhibit 99.1 hereto and is incorporated herein by reference.
As noted in the press release, the Company will host a conference
call at 2:00 PM Eastern Daylight Time (EDT) on Thursday, June 15,
2017, to provide a general business update. Elite will respond to
various stockholder questions submitted prior to the call.
Conference Call Information
| Date: | Thursday, June 15, 2017 |
| Time: | 2:00 PM EST |
| Dial-in numbers: | 1-800-346-7359 (domestic) |
| 1-973-528-0008 (international) | |
| Conference number: | |
| Questions: |
[email protected] by 9:00 AM on Thursday, June 15, 2017 |
| Audio Replay: | http://ir.elitepharma.com/events_presentations |
Item 7.01Regulation FD Disclosure.
The information disclosed in Item 2.02 above is incorporated into
this Item 7.01. The information included in this Current Report
on Form 8-K (including the exhibit hereto) is being furnished
under Item 2.02, Results of Operations and Financial Condition,
Item 7.01, Regulation FD Disclosure and Item 9.01 Financial
Statements and Exhibits of Form 8-K. As such, the information
(including the exhibit) herein shall not be deemed to be filed
for the purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that Section, nor shall it be incorporated by
reference into a filing under the Securities Act of 1933, as
amended, or the Exchange Act, regardless of any general
incorporation language in such filing, except as shall be
expressly set forth by specific reference in such a filing. This
Current Report (including the exhibit hereto) will not be deemed
an admission as to the materiality of any information required to
be disclosed solely to satisfy the requirements of Regulation FD.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release dated June 14, 2017 |
About ELITE PHARMACEUTICALS, INC. (OTCMKTS:ELTP)
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is principally engaged in the development and manufacture of oral, controlled-release products. The Company develops and manufactures generic products, products using controlled-release drug technology, products utilizing abuse deterrent technologies, and it develops and markets generic controlled-release and abuse deterrent pharmaceutical products. Its segments include Abbreviated New Drug Applications (ANDA’s) for generic products and New Drug Applications (NDA’s) for branded products. The Company owns approximately six different approved ANDA’s. The Company’s product, SequestOx, is an immediate-release Oxycodone Hydrochloride containing sequestered Naltrexone, which incorporates five milligram, 10 milligram, 15 milligram, 20 milligram and 30 milligram doses of oxycodone into capsules. SequestOx is used for the management of moderate to severe pain where the use of an opioid analgesic is appropriate.
